In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

You recently wrote about a study regarding aspirin therapy for people with high Lp(a) levels. What is the current thinking?

Team's approach underscores urgency of comprehensive management to confront myriad challenges of the condition ...

Even if no one in your household had the problem, why would you want to risk embarrassing a guest? Most likely almost everyone has had this experience at least once or twice. Couldn’t the problem be ...

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

to select Repatha ® (evolocumab) as the exclusive PCSK9 category product over Praluent ® (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State ...

This drug has been a life-extender for me. A. Thank you for sharing your experience. Evolocumab (Repatha) dramatically lowers LDL cholesterol and reduces the risk of serious cardiovascular events ...

to select Repatha ® (evolocumab) as the exclusive PCSK9 category product over Praluent ® (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State Donnelly ...